Gilead Sciences' hepatitis C treatment Sovaldi, sold at roughly $1,000 per pill, has made headlines for both its price tag and effectiveness. But, the drugs record sales may now be on the decline, according to a Medscape report.
A CVS Health Corp. study demonstrated that the drug's sales have plateaued and declined over the past few months. The study also found discontinuation rates of the drug were 8.1 percent, nearly four times higher than those in trials, according to the report.
More articles on gastroenterology:
New GI technology: 10 gastroenterologists on the most exciting advancements
Are current endoscope cleaning protocols enough?
A promising treatment for pancreatic cancer?
A CVS Health Corp. study demonstrated that the drug's sales have plateaued and declined over the past few months. The study also found discontinuation rates of the drug were 8.1 percent, nearly four times higher than those in trials, according to the report.
More articles on gastroenterology:
New GI technology: 10 gastroenterologists on the most exciting advancements
Are current endoscope cleaning protocols enough?
A promising treatment for pancreatic cancer?